期刊文献+

胞必佳治疗恶性胸腔积液近期疗效观察 被引量:4

Immediate effect of N CWS in treatment of malignant pleural effusion
下载PDF
导出
摘要 目的:评价胞必佳( N C W S) 联合全身化疗及单纯全身化疗对恶性胸腔积液的治疗作用。方法:75 例恶性胸腔积液患者随机分为联合组( 胞必佳胸腔内注射加全身化疗) 及单用全身化疗组两组。结果:联合组的有效率为91 .9 % ,优于单用全身化疗组的有效率57 .9 % ( P< 0 .01) 。结论:胞必佳胸腔内注射联合全身化疗优于单纯化疗控制胸水的疗效,值得临床推广应用。 Objective:To evaluate results of N CWS(nocardia rubra cell wall skeleton) treatment through intravenous route or in combination with intrapleural instillation in malignant pleural effusion.Methods:Seventy five cases of malignant pleural effusion were divided at random into intrapleural and intravenous in combination treated group and intravenous alone treated group.Results:The effective rate of intrapleural and intravenous in combination treated group was 91.9% and the effective rate of intravenous alone treated group was 57.9%.The difference between two groups was sigificant( P <0.01).Conclusions:The effect of intrapleural and intravenous treatment of N CWS in combination is better than intravenous treament alone in malignant pleural effusion.Therefore it is a method of choice in clinic.
出处 《蚌埠医学院学报》 CAS 1999年第6期395-396,共2页 Journal of Bengbu Medical College
关键词 胸腔积液 肿瘤 药物疗法 胞必佳 pleural effusion tumour/chemotherapy nocardia rubra cell wall skeleton(N CWS)
  • 相关文献

参考文献2

二级参考文献1

  • 1胡英华,战义三,于景芳.N-CWS对癌性胸腔(心包)积液14例疗效观察[J]实用内科杂志,1986(11).

共引文献21

同被引文献22

  • 1陈曼萍.胞必佳联合化疗治疗晚期恶性肿瘤的临床观察[J].肿瘤研究与临床,2001,13(3):197-198. 被引量:1
  • 2华新民,卢卫平,段贵新,王启文,刘建阳.顺铂、硫代硫酸钠双途径化疗治疗恶性胸腔积液[J].中华肿瘤杂志,1995,17(1):50-52. 被引量:128
  • 3焦小龙.胸腹腔分流术治疗顽固性恶性胸腔积液[J].国外医学(肿瘤学分册),1995,22(4):229-231. 被引量:22
  • 4王金万,张和平,孙燕.揽香烯乳治疗晚期恶性肿瘤的Ⅱ期临床试用结果[J].中国新药杂志,1995,4(2):25-30. 被引量:45
  • 5李振 许德顺.恶性肿瘤的化学治疗与免疫治疗[M].北京:人民卫生出版社,1993.63.
  • 6[4]Mukai S,Kato H,Kimura,et al.Adoptive immunotherapy ofpoorly immunogenic tumors with in vitro sensitized cells generated by Intratumoral adminitration of biological response modifiers.Int J Immunophamaeol,1995,17(12):963
  • 7[5]Miyzaki K,Yasamoto K,Yano T,et al.Synergistic effect of Noeadia rubra cell wall skeleton and recombinant interlenkin 2 for in vivo induction of lymphokine-Activated killer cells.Cancer Res,1991,51(19):5261
  • 8[6]Innmura N,Sone S,Ogana T,et al.Human blood monocyteacfivatfion by Nocadia rubra cell wall skelefon for production ofinterlenkin 1 and tumor necrosis factor-alpha.Biotherapy,1992,4(2):155
  • 9Bitran JD,Broun JFB,Me Bech F,et al.Intracavity bleomycin for the control of malignant effusion.J Surg Oncol USA,1981,16(3):273 ~277.
  • 10Ostrowski MJ,Halsall GM.Intracavity bleomycin in the management of malignant effusions.A Multicenter Study Cancer Treatment Reports,1986,66:1903 ~ 1907.

引证文献4

二级引证文献22

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部